Use of real-world evidence is becoming increasingly common to aid the clinical development process and provide important data for pricing discussions once medicines have been approved.
Amanda Barrell speaks to the ABPI deputy chief scientific officer Sheuli Porkess and the NIHR’s Simon Denegri at the Pioneering Partnerships conference to find out how they are helping to m
'Prevention' might be the buzzword of the moment in the pharma industry, but what does it actually mean for a company to intercept diseases before they even present clinically?
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.